---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009536"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:46:49.918006+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma raises $46,875 via convertible note at 35% discount and 8% interest

## Summary
- Principal amount $50,000; purchase price $46,875; net proceeds for working capital.
- Conversion price = 65% of lowest closing trade price over prior 10 trading days (35% discount).
- Interest 8% per annum (16% on default); maturity March 1, 2024 (same as issuance date).
- Prepayment rights within 180 days at 110% to 125% premium; no prepayment after 180 days.
- Note issued under Regulation D, unregistered; subject to 4.99% beneficial ownership limitation.

## SEC filing metadata
- accession: 0001493152-24-009536
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315224009536/0001493152-24-009536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315224009536/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009536
- JSON: https://secwatch.observer/filing/0001493152-24-009536.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009536.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $50,000 with an investor at eight percent (8%) per annum, which may be increased to sixteen percent (16%) in maturing March 1, 2024.
  - Instrument: convertible notes
  - Principal: $50,000
  - Counterparty: an investor
  - Rate: eight percent (8%) per annum, which may be increased to sixteen percent (16%) in
  - Maturity: March 1, 2024
  - Event: incurrence
  source text: Effective March 5, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $50,000 (the “Note”), for a purchase price of $46,875.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315224009536/0001493152-24-009536-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at $50,000 (effective 2024-03-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an investor
  - Value: $50,000
  - Effective: 2024-03-05
  source text: Effective March 5, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $50,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315224009536/0001493152-24-009536-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.